What Medications Can Cause Stuttering?

Dozens of medications across several drug classes have been linked to the onset of stuttering in people who never stuttered before. A comprehensive literature review identified 27 individual drugs responsible for 86 documented episodes of drug-induced stuttering, with antipsychotics accounting for the largest share. The condition tends to resolve when the offending medication is stopped or adjusted, but recognizing it as a drug side effect rather than a new neurological problem is the critical first step most people and even some clinicians miss.

Which Drug Classes Are Most Often Involved

A 2022 review of the published literature found that antipsychotic medications were responsible for roughly 57% of all reported drug-induced stuttering episodes, with clozapine leading that group. Central nervous system agents accounted for about 12% of episodes, and anticonvulsant drugs made up about 9%.¹ Beyond these top categories, case reports have implicated antidepressants, ADHD medications, and even a common asthma drug. The list is broader than most people expect, and the categories do not always line up neatly with what you might guess about how each drug works.

Antipsychotics

Antipsychotic medications dominate the case literature on drug-induced stuttering. Both older (“typical”) and newer (“atypical”) antipsychotics have been reported to trigger stuttering, but atypical antipsychotics appear far more frequently in published cases. A case series specifically examining olanzapine and clozapine found seven patients who developed stuttering while on those drugs. Six of the seven were taking olanzapine. None had any history of stuttering beforehand, and none showed other motor side effects like restlessness or a general decline in functioning. Stuttering appeared anywhere from two to 21 days after starting the medication and stopped within two to five days of discontinuing it.²

Clozapine, often reserved for treatment-resistant schizophrenia, has the most reports overall in the broader literature. This matters because patients on clozapine typically have fewer medication alternatives, which makes the clinical decision about what to do next more complicated. The stuttering that antipsychotics produce can cause real social harm, especially for people already managing a psychiatric condition and the stigma that comes with it. It may be overlooked by clinicians who attribute new speech difficulties to the underlying psychiatric illness rather than to the medication itself.³

Antidepressants and Bupropion in Particular

Among antidepressants, bupropion stands out. Unlike most antidepressants that work primarily on serotonin, bupropion blocks the reuptake of both norepinephrine and dopamine, keeping more dopamine active in the brain. Because excess dopamine activity in the basal ganglia is one of the main suspected mechanisms behind stuttering, bupropion’s pharmacology makes it a logical candidate for triggering the condition. Case reports have described patients developing stuttering after starting bupropion, with the stuttering resolving once the drug was stopped.⁴

Selective serotonin reuptake inhibitors (SSRIs), the most commonly prescribed class of antidepressants, have also appeared in case reports of drug-induced stuttering, though less frequently. Changes in serotonin levels have been proposed as one of several pathways that can disrupt speech fluency.⁵ If you develop new speech disruptions after starting or switching an antidepressant, the timing is worth mentioning to your prescriber, even if it feels unrelated.

ADHD Medications

Stimulant medications used for ADHD, particularly methylphenidate (sold under brand names like Ritalin and Concerta), have a notable signal in global safety databases. An analysis of the World Health Organization’s pharmacovigilance database identified 45 cases of methylphenidate-induced stuttering. The median age of affected patients was 10, and about 82% were male. In the vast majority of cases, stuttering improved or disappeared when methylphenidate was stopped, and in five cases where the drug was restarted, stuttering came back.⁶

This finding is worth knowing because ADHD medications are prescribed to millions of children and adults. A broader analysis of the WHO database found that five of the top 20 drug-stuttering associations with the highest disproportionality were ADHD medications.⁵ The stuttering is still considered a rare side effect, but when it affects a child who is already navigating school and social pressures, even a rare side effect deserves prompt attention. Parents sometimes assume the stuttering is developmental and unrelated to a new prescription, which can delay a simple fix.

Other Medications Worth Knowing About

Anticonvulsant drugs, used for epilepsy and sometimes mood stabilization, account for about 9% of reported drug-induced stuttering episodes. Beyond those, a few less obvious medications have been linked to stuttering in case reports and pharmacological analyses:

Theophylline: Used primarily for asthma and other respiratory conditions, theophylline has been associated with stuttering. Pharmacological research suggests it triggers a surge of dopamine in the basal ganglia by blocking adenosine and GABA receptors, creating a brain-chemistry environment that mirrors some of the disruptions seen in developmental stuttering.⁷
Anxiolytics: Certain anti-anxiety medications have appeared in reports, and in a study of military veterans with acquired stuttering, over two-thirds of those who stuttered were taking at least one medication known to affect speech fluency, including anxiolytics.⁵

The theme across all these drug classes is that medications touching the brain’s dopamine, serotonin, GABA, or acetylcholine systems can, in certain individuals, tip speech fluency off balance.

Why These Drugs Disrupt Speech

The brain circuitry that produces fluent speech relies on finely tuned signaling between several chemical messenger systems. When a medication alters the balance of these messengers, the motor planning and timing of speech can break down. Several pathways have been identified as probable culprits: elevated dopamine levels, reduced GABA activity, anticholinergic effects (where a drug blocks the neurotransmitter acetylcholine), and shifts in serotonin.⁵

Of these, dopamine gets the most attention. The basal ganglia, a cluster of structures deep in the brain involved in coordinating movement, are heavily dependent on dopamine signaling. Both too much and too little dopamine activity in this region can cause motor problems, including disruptions to the rapid, precise muscle movements that produce speech. This explains the seeming paradox that both dopamine-boosting drugs (like stimulants and bupropion) and dopamine-blocking drugs (like antipsychotics) can trigger stuttering. The system needs the right amount of dopamine in the right place, and pushing it in either direction can break down fluency.

The Risperidone Paradox

Risperidone provides a striking illustration of how complicated drug-induced stuttering can be. This medication is a potent blocker of both dopamine and serotonin receptors, and it has actually been used to treat stuttering by tamping down dopamine activity in the brain’s motor circuits. In some patients, it works. But in others, risperidone itself causes stuttering. A case report described a patient who developed stuttering during chronic, low-dose risperidone treatment, a scenario the authors noted had not been reported before at that dose and duration.⁸

This paradox is not unique to risperidone. Methylphenidate, a stimulant that boosts dopamine, has also been explored experimentally as a treatment for stuttering while simultaneously appearing in safety databases as a cause of stuttering.⁵ The takeaway for patients is that there is no simple rule like “dopamine-blockers are safe for speech.” Individual brain chemistry, dose, and the specific receptor profile of the drug all matter in unpredictable ways.

How Quickly It Starts and How Quickly It Stops

One of the more reassuring aspects of drug-induced stuttering is the timeline. Onset is usually rapid relative to when the drug was started. In the olanzapine and clozapine case series, stuttering appeared within two to 21 days of beginning treatment and resolved within two to five days of stopping the medication.² Across the broader literature, the pattern holds: in about 56% of all documented episodes, the offending drug was withdrawn, and every one of those patients experienced significant improvement or complete resolution of their stuttering.¹

This rapid resolution is one of the key features that distinguishes drug-induced stuttering from other forms of acquired stuttering caused by stroke or brain injury, where recovery tends to be slower and less predictable. The tight link between starting the drug and developing symptoms, followed by improvement when the drug is removed, also provides the strongest clinical evidence that the medication was the cause.

Who Is Most at Risk

The published case literature skews heavily male and toward adults in their 30s and 40s.¹ For methylphenidate specifically, the demographic is younger, with a median age of 10 and a similarly male-predominant pattern.⁶ Whether males are genuinely more susceptible or simply more represented in the populations taking these drugs is not entirely clear. Men are prescribed antipsychotics and ADHD medications at higher rates, so the gender skew may partly reflect prescribing patterns rather than biology.

A history of developmental stuttering (stuttering as a child) is sometimes mentioned as a possible risk factor, though many of the documented cases occurred in people with no prior history whatsoever. The olanzapine case series specifically noted that all affected patients had no history of stuttering.² A study of military veterans found that more than two-thirds of those who developed acquired stuttering were on at least one medication that could affect speech fluency, compared with about a third of veterans without stuttering.⁵ Being on multiple medications that influence the same brain-chemistry pathways may compound the risk.

What Drug-Induced Stuttering Actually Sounds Like

Drug-induced stuttering shares many of the same outward speech features as the developmental stuttering that starts in childhood, including repetitions of sounds, syllables, and words, as well as prolongations and blocks.⁹ Repetitions appear to be the most common feature in drug-induced cases specifically.¹

This overlap in surface features means a clinician listening to someone with drug-induced stuttering cannot distinguish it from developmental stuttering by sound alone. The critical distinguishing factor is context: a new onset of stuttering in an adult, especially one who recently started or changed a medication, should prompt consideration of a drug-related cause. If the person has no prior history of stuttering, the medication link becomes even more likely. Drug-induced stuttering is classified as a form of neurogenic stuttering, meaning it originates from a disruption in the nervous system rather than from the developmental speech patterns that begin in childhood.¹

What to Do If You Suspect a Medication

If you notice new or worsening stuttering after starting a medication, the most productive step is to bring it up with your prescriber and describe the timeline clearly. When it started, which medication was most recently added or changed, and whether the stuttering fluctuates with dose timing are all useful details. Drug withdrawal or dose adjustment is often enough to resolve the problem.³ In the reviewed literature, stopping the medication led to improvement or complete relief in every case where discontinuation was chosen.

The complication, of course, is that you may genuinely need the medication. Antipsychotics for psychosis, stimulants for ADHD, antidepressants for depression: these are not optional treatments for many people. In those situations, the prescriber may try lowering the dose, switching to a different medication within the same class, or switching classes entirely. Because the underlying brain-chemistry pathways differ from drug to drug, a medication that causes stuttering in one person may not do so for a closely related drug. There is no universal rule that says an entire class is off-limits.

When Speech Therapy Helps

In some cases, even after the offending medication is adjusted, residual stuttering or the psychological effects of the experience can linger. A recent case study demonstrated that speech therapy targeting not just speech fluency but also the emotional and cognitive responses to stuttering led to meaningful improvements in quality of life, stuttering severity, and how the person felt about their speech.¹⁰

This is an underappreciated angle. Even a brief episode of stuttering can leave someone anxious about speaking, avoidant of social situations, or hyper-aware of their speech in ways that perpetuate disfluency. For people who stuttered for weeks or months before the cause was identified, therapy that addresses those secondary effects can be just as important as resolving the pharmacological trigger. The approach is different from traditional stuttering therapy for children; it focuses more on reducing avoidance behaviors and rebuilding confidence in communication rather than on drilling fluency techniques.

Why Drug-Induced Stuttering Goes Unrecognized

Despite the clear pattern in the literature, drug-induced stuttering is widely under-recognized in clinical practice. Part of the problem is that stuttering is not on most prescribers’ radar as a possible drug side effect. It does not appear prominently in prescribing information for most of the implicated medications, and when a psychiatric patient begins stuttering, the instinct is often to attribute it to the underlying condition or to general cognitive decline rather than to the drug. One review described it as “not a negligible adverse drug reaction” that “can significantly affect the quality of life if not treated.”¹

Pharmacovigilance researchers have tried to address this gap by mining large global adverse-event databases. Analyses of the WHO’s VigiBase database and the FDA’s Adverse Event Reporting System have used statistical methods to flag drug-stuttering associations that rise above background noise.¹¹¹² These databases depend on voluntary reporting, which means the true frequency of drug-induced stuttering is almost certainly higher than what the numbers suggest. Many patients never report it, many clinicians never ask, and some episodes resolve when a medication is adjusted for other reasons without anyone connecting the dots.

For patients, the practical implication is straightforward: if you develop stuttering after starting or changing any medication, especially one that affects the brain, do not assume it is unrelated. The connection may be more common than the sparse mention in your medication’s side-effect list would suggest, and the fix is often simpler than you would expect.

1
PubMed Central. Drug-induced stuttering: A comprehensive literature review
2
PubMed. Olanzapine- and clozapine-induced stuttering. A case series
3
European Psychiatry. Drug-induced stuttering: Focus on medication with Antipsychotics
4
PubMed Central. Bupropion-Induced Stuttering
5
PubMed Central. Drug-Induced Stuttering: Occurrence and Possible Pathways
6
PubMed Central. Methylphenidate and stuttering
7
Medical Hypotheses. Neuropharmacology of theophylline induced stuttering: the role of dopamine, adenosine and GABA
8
PubMed Central. A Case of Risperidone Induced Stuttering as a Paradox
9
PubMed Central. Characterizing drug-induced stuttering in electronic health records
10
PubMed. Drug-induced stuttering: A case study
11
PubMed. Drug induced stuttering: pharmacovigilance data
12
PubMed. Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System